[CAS NO. 136790-76-6] Lubiprostone

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [136790-76-6]

Catalog

HY-B0679

Brand

MCE

CAS

136790-76-6

DESCRIPTION [136790-76-6]

Overview

MDL	MFCD20268389
Molecular Weight	390.46
Molecular Formula	C20H32F2O5
SMILES	O=C(C(F)(F)CCCC)CC[C@@H]([C@@H](C1)O)[C@H](C1=O)CCCCCCC(O)=O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Dig Dis Sci. 2019 Sep;64(9):2527-2537.

Summary

Lubiprostone(SPI-0211;RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation. Target: Others Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase motility, and promote spontaneous bowel movements (SBM). From Wikipedia.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01085643	Cedars-Sinai Medical Center\|Takeda Pharmaceuticals North America, Inc.	Constipation-predominant Irritable Bowel Syndrome	March 2010	Not Applicable
NCT00662363	Shirley Ryan AbilityLab\|Takeda Pharmaceuticals North America, Inc.	Constipation	April 2008	Not Applicable
NCT01447849	Texas Tech University Health Sciences Center, El Paso	Constipation	August 2011	Phase 2\|Phase 3
NCT01372423	Anchen Pharmaceuticals, Inc\|Novum Pharmaceutical Research Services	Chronic Idiopathic Constipation	May 2011	Phase 3
NCT00934479	Mayo Clinic\|Arizona State University\|Takeda Pharmaceuticals North America, Inc.	Other Constipation\|Irritable Bowel Syndrome	April 2010	Phase 1
NCT02481947	Braintree Laboratories	Chronic Idiopathic Constipation	May 2015	Phase 3
NCT00399542	Sucampo Pharma Americas, LLC\|Sucampo Pharmaceuticals, Inc.\|Mallinckrodt	Irritable Bowel Syndrome\|Constipation	May 2005	Phase 3
NCT04361656	Ascension South East Michigan	Colonoscopy Preparation	May 1, 2020
NCT01993875	Mallinckrodt\|Sucampo Pharma Americas, LLC\|Takeda\|Sucampo AG	Chronic Idiopathic Constipation	October 2013	Phase 3
NCT01166789	University of North Carolina, Chapel Hill\|Takeda	Irritable Bowel Syndrome	February 2008	Phase 1
NCT01469819	Texas Tech University Health Sciences Center, El Paso\|Takeda Pharmaceuticals North America, Inc.	Chronic Idiopathic Constipation	June 2012	Phase 2\|Phase 3
NCT01170039	Emory University	Constipation\|Diabetes	September 2010	Phase 4
NCT00689026	Augusta University\|Takeda Pharmaceuticals North America, Inc.	Diabetes Mellitus, Type 1\|Diabetes Mellitus, Type 2	May 2008	Not Applicable
NCT00597428	Sucampo Pharma Americas, LLC\|Sucampo Pharmaceuticals, Inc.\|Mallinckrodt	Opioid-Induced Bowel Dysfunction	August 2007	Phase 3
NCT03097861	Sucampo Pharma Americas, LLC\|Sucampo AG\|Sucampo Pharmaceuticals, Inc.\|Mallinckrodt	Chronic Idiopathic Constipation	March 13, 2017	Phase 3
NCT02695719	Takeda	Chronic Idiopathic Constipation	April 14, 2016	Phase 3
NCT00953043	Mayo Clinic\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Center for Research Resources (NCRR)\|Takeda	Healthy	September 2007	Phase 4
NCT01298219	Sucampo Pharma Americas, LLC\|Sucampo Pharmaceuticals, Inc.\|Mallinckrodt	Opioid-induced Bowel Dysfunction	December 2010	Phase 3
NCT01096290	University of South Alabama\|Takeda\|Sucampo Pharmaceuticals, Inc.	Constipation	April 2010	Phase 4
NCT02651155	Takeda	Constipation	March 2, 2016	Phase 3
NCT01674530	Dr. Reddy´s Laboratories Limited\|Parexel	Chronic Idiopathic Constipation	October 2012	Phase 3
NCT01162863	University of Michigan\|Takeda Pharmaceuticals North America, Inc.	Irritable Bowel Syndrome\|Constipation	November 2010	Not Applicable
NCT01839734	Ruth M. Rothstein CORE Center	HIV	June 2013	Phase 2
NCT00844831	University of Louisville\|Takeda	Constipation	May 2009	Phase 4
NCT00595946	Sucampo Pharma Americas, LLC\|Sucampo Pharmaceuticals, Inc.\|Mallinckrodt	Opioid-Induced Bowel Dysfunction	August 2007	Phase 3
NCT00380250	Sucampo Pharma Americas, LLC\|Takeda\|Mallinckrodt	Irritable Bowel Syndrome With Constipation	May 2005	Phase 3
NCT01236534	University of Rochester\|Takeda	Multiple Sclerosis\|Constipation	November 2010	Phase 4
NCT04138004	Rajavithi Hospital	Indication for Modification of Patient Status (Diagnosis)	December 1, 2019	Phase 4
NCT02544152	Sucampo Pharma Americas, LLC\|Takeda\|Sucampo AG\|Mallinckrodt	Irritable Bowel Syndrome	February 2015	Phase 2
NCT00706004	University of Arkansas\|Takeda Pharmaceuticals North America, Inc.	Constipation\|Cystic Fibrosis	July 2008	Not Applicable
NCT03010631	Sucampo Pharma Americas, LLC\|Takeda\|Mallinckrodt	Healthy Volunteers	November 16, 2016	Phase 3
NCT02138136	Sucampo Pharma Americas, LLC\|Takeda\|Mallinckrodt	Constipation - Functional	February 26, 2014	Phase 3
NCT01324284	Asian Institute of Gastroenterology, India	Colorectal Carcinoma	March 2011	Phase 3
NCT00953017	Brooke Army Medical Center	Colonoscopy	July 2009	Phase 4
NCT01460225	Dartmouth-Hitchcock Medical Center\|Takeda Pharmaceuticals North America, Inc.	Chronic Idiopathic Constipation	September 2007	Phase 4
NCT02766777	Sucampo Pharma Americas, LLC\|Sucampo AG\|Mallinckrodt	Constipation - Functional	April 12, 2016	Phase 3
NCT00620061	Sucampo Pharma Americas, LLC\|Mallinckrodt	Opioid-Induced Bowel Dysfunction	December 2007	Phase 3
NCT00452335	Sucampo Pharma Americas, LLC\|Sucampo Pharmaceuticals, Inc.\|Mallinckrodt	Constipation	January 2007	Phase 4
NCT00669461	University of Arkansas\|Takeda	Constipation\|Parkinson´s Disease	June 2009	Not Applicable
NCT02042183	Sucampo Pharma Americas, LLC\|Sucampo AG\|Mallinckrodt	Constipation - Functional	December 13, 2013	Phase 3
NCT01190020	Augusta University\|Takeda Pharmaceuticals North America, Inc.	Chronic Constipation, Methanogenesis	February 2009	Phase 1
NCT03720613	BioDelivery Sciences International\|HealthCore, Inc.	Opioid-induced Constipation	January 4, 2019
NCT02729909	Takeda	Constipation	May 11, 2016	Phase 3
NCT05144295	Alexandria University	Clinical Efficacy\|Treatment Efficacy\|Drug Side Effect	January 1, 2022	Phase 3
NCT00746395	University of South Alabama\|Takeda\|Sucampo Pharmaceuticals, Inc.	Inflammatory Bowel Disease	April 2008	Phase 4
NCT00645801	Henry Ford Health System\|Takeda Pharmaceuticals North America, Inc.	Colonoscopy	March 2008	Phase 4
NCT00908076	Baylor College of Medicine\|University of South Florida	Parkinson´s Disease	February 2009	Phase 4
NCT00611442	Brooke Army Medical Center\|Takeda	Bowel Preparation for Colonoscopy	October 2007	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 256.11 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5611 mL	12.8054 mL	25.6108 mL
5 mM	0.5122 mL	2.5611 mL	5.1222 mL
10 mM	0.2561 mL	1.2805 mL	2.5611 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 3.25 mg/mL (8.32 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 3.25 mg/mL (8.32 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 3.25 mg/mL (8.32 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] http://en.wikipedia.org/wiki/Lubiprostone

Synonyms

Prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11α)-

(11α)-16,16-Difluoro-11-hydroxy-9,15-dioxoprostan-1-oic acid

RU 0211

Lubiprostone